A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
Frontiers in Pharmacology · 21.12.2023 · 14
DOI: 10.3389/fphar.2023.1320458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 21.12.2023. Verfasst von Fan Zou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, China. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mepolizumab is primarily used in the treatment of asthma, eosinophilic granulomatosis with polyangiitis, eosinophilia syndrome, and chronic rhinitis with nasal polyps. The information about its adverse drug reactions is mainly derived from clinical trials, and there is a shortage of real-world studies with extensive sample sizes. In this study, the U.S. FDA’s Adverse Event Reporting System (FAERS) database was analyzed to evaluate the side effects of mepolizumab. A total of 18,040 reports of mepolizumab-associated adverse events were identified from the FDA Adverse Event Reporting System database. Multiple disproportionality analysis algorithms were used to determine the significance of these AEs. The study identified 198 instances of mepolizumab-induced AEs, including some important AEs not mentioned in the product labeling. The time to onset of adverse reactions was also analyzed, with a median time of 109 days. Most AEs occurred within the first month of mepolizumab use, but some may still occur after 1 year of treatment. Gender-specific analysis showed different high-risk AEs for females (digestive and neurological side effects) and males (serious adverse effects leading to hospitalization and death). The findings mentioned provide valuable insights on optimizing the use of mepolizumab, enhancing its effectiveness, and minimizing potential side effects. This information will greatly contribute to the practical implementation of the drug in clinical settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Zitieren
APA
Zou, F., Zhu, C., Lou, S., Cui, Z., Wang, D., Ou, Y., Wang, L., Chen, J., & Lan, Y. (2023). A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1320458
Vancouver
Zou F, Zhu C, Lou S, Cui Z, Wang D, Ou Y, et al. A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1320458
BibTeX
@article{Zou2023,
author = {Zou, Fan and Zhu, Chengyu and Lou, Siyu and Cui, Zhiwei and Wang, Dan and Ou, Yingyong and Wang, Li and Chen, Junyou and Lan, Yuanbo},
title = {A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1320458}
}
EUVIMED